What Is Melanotan I Peptide?
Melanotan I, also known as NDP-MSH or [Nle4,D-Phe7]-α-MSH, is a synthetic analogue of α-melanocyte-stimulating hormone (α-MSH). It contains 13 amino acids and differs from native α-MSH at two positions: norleucine replaces methionine at position 4, while D-phenylalanine replaces L-phenylalanine at position 7.
Melanotan I is classified as a synthetic melanocortin peptide analogue. Its modified peptide sequence has been studied as a structural analogue of α-MSH in research on melanocortin biology. The compound is identified in the scientific literature as [Nle4,D-Phe7]-α-MSH, NDP-MSH, and Melanotan I.
Research Overview Table
Chemical and Molecular Characteristics
Certificates:
Melanotan I is a 13-amino-acid synthetic analog of α-MSH. Its sequence contains norleucine at position 4 and D-phenylalanine at position 7, replacing methionine and L-phenylalanine in the corresponding positions of α-MSH. The peptide also has an N-terminal acetyl group and a C-terminal amide.
These sequence modifications distinguish Melanotan I from native α-MSH while retaining the characteristic 13-residue peptide architecture. The defined amino acid sequence, terminal modifications and stereochemistry are its principal chemical characteristics and provide the basis for distinguishing the compound from related melanocortin peptide analogs.
Mechanism of Action Under Investigation
Melanotan I (NDP-MSH) acts as an agonist at the melanocortin-1 receptor (MC1R), a G protein-coupled receptor. Studies using human MC1R have identified several receptor residues involved in NDP-MSH binding. Mutations of acidic residues such as Glu94, Asp117, and Asp121 altered NDP-MSH binding affinity or signaling potency. Mutations involving aromatic residues in transmembrane regions 4–6 also affected ligand–receptor interactions, indicating that multiple receptor regions contribute to NDP-MSH recognition.
MC1R activation by NDP-MSH stimulates adenylyl cyclase and increases intracellular cyclic AMP (cAMP). Experimental studies have measured NDP-MSH-induced cAMP accumulation in cells expressing human MC1R. NDP-MSH has also been shown to activate ERK1/2 signaling in human melanoma cells. These findings indicate that MC1R signaling involves both the canonical cAMP pathway and an ERK pathway, although the molecular relationship between these pathways is not completely defined.
The precise contribution of individual MC1R residues to ligand binding and receptor activation remains under investigation. Mutations can produce different changes in binding affinity and signaling potency. showing that these processes are not always directly correlated. MC1R genetic variants can also alter signaling responses to NDP-MSH.
Scientific Research Context
Melanotan I has progressed from early experimental studies of synthetic melanocortin peptides to investigations in human subjects. The literature includes in vitro receptor and cell studies, preclinical animal research, pharmacological studies, and clinical investigations. This gives the compound a mixed evidence base spanning laboratory and human research, rather than a literature limited to early-stage experimental work. The amount of evidence is not uniform across these areas, with substantially more research available for some aspects of Melanotan I than others.
Melanotan I Biology and Biological Pathways
Primary Biological Function
MC1R is a G protein-coupled receptor expressed in cutaneous and hair-follicle melanocytes. It is an important regulator of melanocyte function and pigmentation biology. MC1R signaling is associated with the balance between eumelanin and pheomelanin production. Researchers investigate this receptor to understand melanocyte biology, pigmentation, and variation in melanocortin signaling.
Relevant Metabolic or Signaling Pathways
MC1R is primarily coupled to the adenylyl cyclase–cAMP pathway. Increased cAMP activates protein kinase A and downstream CREB signaling, which regulates MITF, a transcription factor involved in melanocyte differentiation and melanogenic gene expression. The pathway includes genes such as TYR, DCT, and TYRP1. ERK signaling has also been studied in MC1R biology, although its relationship with the cAMP pathway is more complex.
Tissue-Specific Biology
MC1R has been studied mainly in melanocytes located in the epidermis and hair follicles. In the skin, melanocytes produce melanin within melanosomes and transfer these organelles to surrounding keratinocytes. Hair-follicle melanocytes represent another distinct system in which MC1R-related signaling and pigmentation are investigated. Differences in MC1R sequence and function can also produce variation in melanocyte responses.
Experimental Biomarkers
Researchers measure melanin content, tyrosinase activity, and melanogenic gene expression in studies of NDP-MSH-treated melanocytes. In cultured human melanocytes, published research measured tyrosinase mRNA and tyrosinase-related protein-1 (TRP-1) mRNA alongside melanin content and tyrosinase activity. Studies using melanocytes with different MC1R variants have also examined dopachrome tautomerase (DCT) expression as a pigmentation-related marker.
Laboratory Investigation Methods
Melanotan I (NDP-MSH) has been studied in cultured human melanocytes and MC1R-expressing cells. Cellular experiments measure melanin content, tyrosinase activity, tyrosinase mRNA and TRP-1 mRNA. MC1R studies use radioligand-binding assays and site-directed mutagenesis to examine NDP-MSH binding and identify receptor residues that contribute to ligand recognition. Together, these methods examine both cellular responses and the molecular interaction between NDP-MSH and MC1R.
Experimental Models Used in Published Research
Published Melanotan I research has used cultured human melanocytes, MC1R-expressing cell systems, melanocyte–keratinocyte cocultures, animal models, and human participants. These models range from isolated cells and receptor systems to intact organisms. Their limitations mainly involve the simplified conditions of cell-based models, differences between experimental species and humans, and the restricted populations and conditions used in human studies.
Cultured Human Melanocytes
Cultured human melanocytes provide a controlled model for examining Melanotan I in human pigment cells. The model removes whole-body variables while retaining key characteristics of human melanocytes. Its main limitation is the simplified culture environment which does not reproduce intact skin or the normal interactions between melanocytes, keratinocytes, and surrounding tissue.
MC1R-Expressing Cell Systems
Studies have used cells expressing MC1R to examine Melanotan I in a defined receptor system. This model reduces the complexity of intact cells and tissues. Its limitation is that engineered receptor systems may not fully represent native MC1R expression or the cellular environment of human melanocytes.
Melanocyte–Keratinocyte Cocultures
Melanocyte–keratinocyte cocultures have been used as a more representative in vitro model of the epidermal environment. The system includes human melanocytes together with keratinocytes, allowing their interaction to remain part of the experimental model. Its main limitation is that it still does not reproduce the full structure and cellular complexity of intact human skin.
Animal Models
Animal studies have used guinea pigs and mice to investigate Melanotan I (NDP-MSH). Guinea pigs provide an intact skin model, while mice have been used in toxicology studies. These models reproduce whole-organism conditions that cell cultures cannot. However, differences in pigmentation, skin structure, metabolism and physiology limit how closely these models represent human biology.
Human Studies
Melanotan I has also been studied in human participants. Human studies avoid interspecies differences and provide a model directly relevant to human biology. Their limitations include selected participant populations, controlled study conditions, and differences in individual MC1R genotypes, which can limit how broadly the model represents the wider population.
Melanotan I Published Research
Human Skin Pigmentation
Research has examined Melanotan I in relation to human skin pigmentation, including changes in skin darkening and the composition of melanin produced in human skin. Studies have also investigated whether Melanotan I alters the balance between eumelanin and pheomelanin. Human clinical studies and skin analyses have both contributed to this area of research.
Melanocyte Biology
Cultured human melanocytes have been used to study NDP-MSH and melanogenesis, including melanin content, tyrosinase activity, and expression of pigmentation-related genes such as TYR and TRP1. Other work has examined NDP-MSH responses in melanocytes with different MC1R variants, including studies using melanocyte–keratinocyte cocultures.
MC1R and Receptor Variation
Studies have investigated how NDP-MSH interacts with MC1R, including the receptor residues involved in ligand binding and receptor activation. Other research has examined naturally occurring MC1R variants and their relationship to responses to NDP-MSH, including differences in pigmentation responses among individuals with different MC1R genotypes.
Pharmacokinetics
Human research has investigated the pharmacokinetics of Melanotan I, including systemic exposure and plasma concentrations following different administration routes.
Limitations of Current Research
Evidence Is Predominantly Preclinical
A key limitation is the reliance on in vitro melanocyte studies for much of the biological evidence. Cultured melanocytes allow controlled testing, but they do not recreate the full cellular and tissue environment of human skin. This makes it difficult to determine how closely laboratory observations reflect biology in intact human tissue.
Human Clinical Evidence
Human evidence is limited by small, selected study populations. One pharmacokinetic study included only three male volunteers, while another randomized study included 77 Caucasian participants. Earlier clinical research also enrolled 28 healthy white men. These study populations limit how confidently researchers can generalize the findings to broader, more diverse groups.
Species Differences
Animal models have limitations because pigmentation, skin biology and physiology vary between species. Guinea pig studies provide an intact biological model, but differences from human skin limit how directly findings from these models can be applied to humans.
Study Design Limitations
The studies differ in sample size, administration route, dosing schedule, and follow-up period. These differences make it harder to compare findings across studies. They also limit the conclusions that can be drawn when individual studies use different experimental designs.
Independent Replication
A limitation is the limited independent replication of specific Melanotan I findings. The published literature includes several studies from related research programs, but relatively few investigations have repeated the same questions using independent research groups, populations and study designs. This makes it harder to assess the consistency of some findings across independent studies.
Long-Term Evidence
Long-term human evidence remains limited. Clinical studies have generally followed participants for weeks to a few months, rather than over extended periods. Longer follow up would be needed to assess whether observations remain consistent over time. The available animal studies do not fill this gap because their results cannot establish long-term outcomes in humans.
Analytical Documentation
HPLC can assess peptide purity and separate Melanotan I from related substances. A validated HPLC method has been used to detect and measure the peptide in cell-culture media and human plasma.
LC-MS can provide additional molecular identification by combining chromatographic separation with mass measurement. Recent work on afamelanotide, also known as Melanotan I, has used LC-high-resolution MS to examine its degradation profile.
NMR can provide structural information for melanocortin peptides and related analogues, although it is not necessarily part of routine Melanotan I product testing.
A Certificate of Analysis (COA) can document tested quality attributes for a specific material or batch. Analytical documentation supports verification of product identity and quality; it does not establish biological performance or therapeutic effects.
Storage and Laboratory Handling
Melanotan I from Direct Sarms Iceland should be stored at 2–8°C when this temperature range is specified for the research material. Keep the material in its original, properly sealed container and protect it from unnecessary temperature changes. Published stability studies show that Melanotan I and its subunits can be affected by storage conditions, particularly higher temperatures.
Laboratory personnel should keep storage and handling areas clean and dry and prevent contact with contaminants. Melanotan I is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs Iceland is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Iceland, we aim to make the research supply process simple, clear, and reliable.


